npj Regenerative Medicine (Sep 2023)

An engineered periosteum for efficient delivery of rhBMP-2 and mesenchymal progenitor cells during bone regeneration

  • Juan Antonio Romero-Torrecilla,
  • José María Lamo-Espinosa,
  • Purificación Ripalda-Cemboráin,
  • Tania López-Martínez,
  • Gloria Abizanda,
  • Luis Riera-Álvarez,
  • Sergio Ruiz de Galarreta-Moriones,
  • Asier López-Barberena,
  • Naiara Rodríguez-Flórez,
  • Reyes Elizalde,
  • Vineetha Jayawarna,
  • José Valdés-Fernández,
  • Miguel Echanove-González de Anleo,
  • Peter Childs,
  • Elena de Juan-Pardo,
  • Manuel Salmeron-Sanchez,
  • Felipe Prósper,
  • Emma Muiños-López,
  • Froilán Granero-Moltó

DOI
https://doi.org/10.1038/s41536-023-00330-2
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 14

Abstract

Read online

Abstract During bone regeneration, the periosteum acts as a carrier for key regenerative cues, delivering osteochondroprogenitor cells and crucial growth factors to the injured bone. We developed a biocompatible, 3D polycaprolactone (PCL) melt electro-written membrane to act as a mimetic periosteum. Poly (ethyl acrylate) coating of the PCL membrane allowed functionalization, mediated by fibronectin and low dose recombinant human BMP-2 (rhBMP-2) (10-25 μg/ml), resulting in efficient, sustained osteoinduction in vitro. In vivo, rhBMP-2 functionalized mimetic periosteum demonstrated regenerative potential in the treatment of rat critical-size femoral defects with highly efficient healing and functional recovery (80%-93%). Mimetic periosteum has also proven to be efficient for cell delivery, as observed through the migration of transplanted periosteum-derived mesenchymal cells to the bone defect and their survival. Ultimately, mimetic periosteum demonstrated its ability to deliver key stem cells and morphogens to an injured site, exposing a therapeutic and translational potential in vivo when combined with unprecedentedly low rhBMP-2 doses.